Valerie P. J. Saw

Valerie P. J. Saw

Auto-generated profile, based on publicly available information

Valerie P. J. Saw

Department of Ocular Biology and Therapeutics, University College London Institute of Ophthalmology, London, United Kingdom

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2008 in Ophthalmology
Verified
Journal Article
Closed access
VSValerie P.J. Saw
Valerie P.J. Saw
JDJohn K.G. Dart
John K.G. Dart
SRSaaeha Rauz
Saaeha Rauz
ARAndrew Ramsay
Andrew Ramsay
CBCatey Bunce
Catey Bunce
MPMelanie Phillips
Melanie Phillips

1 July 2008 in The Ocular Surface
Verified
Journal Article
Closed access
VSValerie P.J. Saw
Valerie P.J. Saw
JDJohn K.G. Dart
John K.G. Dart

1 December 2009 in The American Journal of Pathology
Verified
Journal Article
Closed access
VSValerie P.J. Saw
Valerie P.J. Saw
IOIfeoma Offiah
Ifeoma Offiah
RDRobin Dart
Robin Dart
GGGrazyna Galatowicz
Grazyna Galatowicz
JDJohn K.G. Dart
John K.G. Dart
VCVirginia L. Calder
Virginia L. Calder

1 January 2011 in The American Journal of Pathology
Verified
Journal Article
Closed access
VSValerie P.J. Saw
Valerie P.J. Saw
ESEnno Schmidt
Enno Schmidt
IOIfeoma Offiah
Ifeoma Offiah
GGGrazyna Galatowicz
Grazyna Galatowicz
DZDetlef Zillikens
Detlef Zillikens
JDJulie T. Daniels
Julie T. Daniels

21 February 2007 in British Journal of Ophthalmology
Verified
Journal Article
Closed access
VSV. P J Saw
V. P J Saw
DMD. Minassian
D. Minassian
JDJ. K G Dart
J. K G Dart
ARA. Ramsay
A. Ramsay
HHH. Henderson
H. Henderson
T(the Amniotic Membrane Tissue User Group (AMTUG)
the Amniotic Membrane Tissue User Group (AMTUG)
Amniotic membrane transplantation (AMT), as a new tool in the armamentarium of therapies available for ocular surface problems, became widely available in the UK in 1998. This study evaluates the indications for treatment, the surgical procedures used, and the results of a subset of the first AMT cases carried out by the group using this nationally available supply. This user group model provides data which is different from that obtained from uncontrolled case series, or clinical trials, and may be more representative of the outcomes that can be expected when a procedure becomes widely available. The first 233 AMTs, performed by the UK user group, were evaluated by audit and outcomes were assessed at 3 months. Of the 233 transplants, there were 126 (54.1%) valid outcome returns: the outcome for persistent epithelial defects was a healed and stable surface in 11/35 (31.4%, 95% CI 16.9 to 49.3); for chemical/thermal injuries, a healed uninflamed eye with clear cornea in 5/18 (27.8%, 95% CI 9.7 to 53.4); for bullous keratopathy a pain-free, stable surface without bullae in 4/18 (22.2%, 95% CI 6.4 to 47.6); for ocular surface reconstruction, an epithelialised uninflamed conjunctiva without scarring in 12/23 (52.2%, 95% CI 30.6 to 73.2); and for limbal stem cell deficiency, a corneal phenotype in 4/7 (57.1%). The operative technique least associated with failure was use of a bandage contact lens at the end of the procedure (OR 0.19, 95% CI 0.06 to 0.59, p = 0.004). Previous treatment with topical steroids was significantly associated with failure (OR 5.70, 95% CI 1.77 to 18.43, p = 0.004). Although the outcome criteria used in this study were stringent, and the follow-up duration was short, the results of AMT by this user group were generally less favourable than those of previously reported case series. Controlled clinical trials would improve the quality of evidence for use of amniotic membrane in ocular disease.

1 November 2009 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Open access
PDF file
VSValerie P. J. Saw
Valerie P. J. Saw
RDRobin Dart
Robin Dart
GGGrazyna Galatowicz
Grazyna Galatowicz
JDJulie T. Daniels
Julie T. Daniels
JDJohn K. G. Dart
John K. G. Dart
VCVirginia L. Calder
Virginia L. Calder
Purpose.: First, to determine whether tumor necrosis factor-(TNF)-α is expressed in the conjunctiva of ocular mucous membrane pemphigoid (MMP) and the consequences of systemic immunosuppressive treatment on this expression. Second, to investigate the in vitro effects of TNFα on human conjunctival fibroblasts. Methods.: The expression of TNFα in conjunctival tissues of patients with actively inflamed ocular MMP (n = 10), patients with clinically noninflamed ocular MMP after systemic immunosuppressive treatment (n = 10), and normal subjects (n = 10) was studied by immunohistochemistry. The effect of TNFα on functional assays of human conjunctival fibroblast activity were investigated, including migration, collagen lattice contraction, matrix metalloproteinase (mmp), and tissue inhibitor of matrix metalloproteinase (timp) secretion, proliferation, and surface expression of HLA-DR, ICAM, CD80, CD86, CD40, CD40-ligand. Results.: In active ocular MMP, TNFα is expressed by a large number of stromal infiltrating cells (234 cells/mm2), and although the level of stromal TNFα expression is significantly reduced after immunosuppressive treatment (90 cells/mm2), these levels are still significantly elevated compared with normal conjunctiva (10 cells/mm2, P < 0.05). TNFα stimulates increased migration by conjunctival fibroblasts (P < 0.001), increased production of mmp-9 (P = 0.01), decreased production of timp-2 (P = 0.01) and timp-4 (P = 0.04), and upregulated expression of CD40 and ICAM (P = 0.04). No significant effects of TNFα on fibroblast proliferation or collagen lattice contraction were detected. Conclusions.: Increased conjunctival expression of TNFα in ocular MMP suggests that systemic TNFα antagonists are likely to be effective in controlling severe disease unresponsive to conventional systemic immunosuppression. Residual TNFα expression persists in clinically noninflamed disease. TNFα appears to have profibrotic and proinflammatory effects on human conjunctival fibroblasts.